ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2413

Expression and Function Of a YAP, a Novel Pathway In Fibroblast-Like Synoviocyte In Rheumatoid Arthritis

Beatrix Bartok, Rheumatology, UCSD School of Medicine, La Jolla, CA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Rheumatoid arthritis (RA), synovial cells, synovial fluid and transcription factor

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis: Human Etiology and Pathogenesis II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Modulating molecular pathways that regulate pathogenic behavior fibroblast-like synoviocytes (FLS) could lead to new therapies for rheumatoid arthritis (RA). Targeting transcription factors are especially interesting, because they regulate the expression of multiple genes and therefore regulate diverse pathways that contribute to disease. The transcriptional coactivator YAP is emerging as a major regulator of proliferation, organ size and oncogenesis. Several downstream targets of YAP such as surviving and CTGF are implicated in different aspect of RA; however the YAP pathway itself has not been characterized yet in inflammatory synovitis. Therefore, we explored expression and function of YAP in RA synoviocytes.

Methods: For confocal microscopy cells were starved overnight, fixed and stained for YAP, DAPI, and with phalloidin for F-actin. For quantification, YAP signal was scored as nuclear/nuclear+cytoplasmic versus cytoplasmic only by analyzing 150-200 cells for each cell line. For qPCR analysis the relative abundance of mRNA was calculated by normalizing to GAPDH. For siRNA knockdown, YAP and control siRNA weretransfected using AMAXA technology. To quantify cell proliferation, 5 days following transfection cell were plated in 1% FBS containing media in the presence of absence of TNF (10 ng/ml) and cell number was assayed with MTT on day 0, 2, 4 and 6.

Results:

Using Western blot analysis, YAP protein was abundant and levels were similar in RA and OA FLS (n=4). Next we assayed the subcellular localization of YAP in RA and OA FLS using confocal microscopy. 80% of the RA FLS had nuclear YAP compared with only 40% of OA cells (n=4, p<0.035). These observations suggested that YAP is constitutively active in RA FLS and is increased compared with OA. To confirm YAP transcriptional activity, qPCR was performed for YAP target genes survivin, CTGF and CCN1. mRNA levels for all three were significantly greater in RA compared with OA (n=3, P<0.04 for each). When RA FLS were stimulated with TNF, YAP was dephosphorylated (S473) and underwent nuclear translocation. This was followed by a 2.5 fold (P<0.04) increase in survivin and 1.5 fold (P<0.03) in CTGF mRNA levels (n=3). To determine critical role of YAP in TNF signaling, YAP was knocked down by siRNA and cells were stimulated with TNF. Proliferation increased 1.8 fold in control siRNA treated cells but not in YAP deficient cells (n=3, P<0.03).

Conclusion: This is the first study to demonstrate that YAP is expressed in FLS and that YAP activity is dysregulated in RA compared with OA FLS. Increased YAP activity might contribute to persistent activation and pathogenic behavior of RA FLS, especially TNF-regulated functions. Therefore, reprogramming RA FLS by modulating the YAP pathway represents a novel therapeutic approach for RA.

 


Disclosure:

B. Bartok,
None;

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/expression-and-function-of-a-yap-a-novel-pathway-in-fibroblast-like-synoviocyte-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology